Henrique Kim, Clinical Oncology Resident at A.C.Camargo Cancer Center, shared on LinkedIn:
“I’m very happy to share that our new meta-analysis has been published in ESMO Gastrointestinal Oncology!
Our study included six randomized clinical trials involving more than 2,400 patients with unresectable hepatocellular carcinoma.
Our findings showed that adding immune checkpoint inhibitors to TACE:
- Improved progression-free survival
- Increased objective response rates
- Was associated with higher toxicity
- Showed a borderline overall survival benefit, although the data remain immature and longer follow-up is needed.
I’d also like to thank this incredible team for making this possible, especially Dr. Tiago Cordeiro Felismino and Dr. Angelo Brito, for their amazing mentorship and support throughout this project.”
Title: Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials
Authors: H. Kim, T. C. Felismino, A. Lício Júnior, G. R. Almeida, A. B. C. Brito
Other articles about ESMO on OncoDaily.